Pregnancy of 30 weeks with itching over this area management
Reading File
Finding Sources
Searching PubMed
intrahepatic cholestasis pregnancy management
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have all the information needed for a comprehensive answer.
Clinical Assessment
The image shows pedal edema (swollen foot and ankle). In the context of 30 weeks pregnancy with pruritus over the feet, the leading diagnosis is:
Intrahepatic Cholestasis of Pregnancy (ICP) — pruritus is classically felt on the palms and soles but can affect any body part, including the feet/ankles.
Diagnosis — First Steps
| Investigation | What to look for |
|---|---|
| Serum bile acids | >10 μmol/L = diagnostic; >40 μmol/L = severe |
| LFTs (AST, ALT, bilirubin, GGT) | Elevated transaminases (may precede bile acid rise by weeks) |
| Liver ultrasound | Exclude biliary obstruction, gallstones |
| Hepatitis C serology, ANA | Rule out concurrent hepatitis C, autoimmune hepatitis |
| Repeat tests in 1–2 weeks if normal but pruritus persists | Biochemical changes may lag symptoms |
Note: ICP does not cause a primary skin rash — excoriations from scratching may simulate one. Pedal edema is a common accompaniment in late pregnancy.
Management
1. Pharmacological (Maternal symptoms)
Ursodeoxycholic acid (UDCA) — first-line, only drug with consistent evidence:
- Dose: 10–15 mg/kg/day, started at 500 mg twice daily
- May increase up to 2000 mg/day if needed
- Reduces pruritus, AST, ALT, bilirubin, and bile acid levels
- Most effective when bile acids >40 μmol/L
- Also reduces bile acid levels in cord blood and amniotic fluid, likely reducing fetal risk
Second-line / adjuncts (less evidence):
- Topical aqueous cream with menthol — symptom relief only
- Cholestyramine — anion exchange resin; less effective
- Dexamethasone, S-adenosylmethionine, guar gum — evidence weaker than UDCA
- Rifampicin, opiate antagonists, ondansetron, phototherapy — used for cholestasis-related pruritus in non-pregnant patients; limited data in ICP
2. Fetal Monitoring
| Fetal Concern | Action |
|---|---|
| Spontaneous preterm labor | Vigilant monitoring |
| Fetal asphyxia, meconium staining | Antenatal surveillance (NST, BPP) — though no evidence these definitively prevent stillbirth |
| Sudden fetal death (bile acid-induced arrhythmia) | Heightened awareness; delivery planning |
- Fetal risks are highest when bile acids >40 μmol/L (asphyxia, meconium, preterm)
- Stillbirth risk is significantly elevated only at >100 μmol/L
3. Timing of Delivery
- Early delivery is the only intervention that reduces stillbirth risk
- Standard practice: induce labor at 37 weeks (or earlier if severe disease)
- At 30 weeks: continue pregnancy with close monitoring, UDCA, and serial bile acid levels
- If bile acids escalate to >100 μmol/L or fetal compromise occurs → expedite delivery balancing prematurity risks
4. Counseling
- Recurrence rate in future pregnancies: 40–90%
- Avoid cholestatic antibiotics (erythromycin, flucloxacillin, amoxicillin-clavulanic acid) in future
- Hormonal contraception carries a ~10% risk of pruritus/hepatic impairment in affected women
Summary Algorithm at 30 Weeks
Pruritus + foot swelling at 30 wks
↓
Serum bile acids + LFTs + liver USS
↓
Bile acids >10 µmol/L → ICP confirmed
↓
Start UDCA 500 mg BD (titrate to 10–15 mg/kg/day)
↓
Serial bile acid levels q1–2 weeks
↓
Antenatal surveillance (NST/BPP)
↓
Plan delivery at 37 weeks (or earlier if severe)
Sources: Creasy & Resnik's Maternal-Fetal Medicine, 9th ed., pp. 1582–1584; systematic review [PMID: 39093046] confirms severity-dependent fetal risk.
This is a shared conversation. Sign in to Orris to start your own chat.